MacroGenics | MGNX - Current Assets


MacroGenics reported $321.69M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Daiichi Sankyo JPY 2.23T 91.92B Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Genmab DKK 2.8B 228M Jun/2026
Geron USD 486.34M 12.19M Jun/2026
Gilead Sciences USD 12.53B 6.11B Jun/2026
J&J USD 56.35B 3.42B Sep/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
MacroGenics USD 321.69M 139.16M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Xencor USD 523.21M 40.36M Jun/2026